The drug target identification is the primary step for drug discovery. Recent development of computational techniques and availability of sequencing data has provided numerous opportunities for target identification but very few of them are fully automated. Here, we have developed a Perl program named Dtar-Finder for drug target identification and its characterization. Dtar-Finder predicts the drug targets which are essential to pathogen and non homologous to human, essential human anti-targets and gut microflora. This program is divided in 6 modules where modules 1-4 extract drug targets while module 5-6 predicts druggability and broad spectrum ability of identified candidates. The performance of this program in terms of sensitivity and specificity is calculated where specificity score was better compare to sensitivity score. Further, we have tested our script on C. botulinum (3572 proteins) and 35 potential drug targets have been identified. Out of which 16 broad spectrums candidates were predicted whereas 8 candidates are found to be druggable whiles remaining are considered to be 'novel'. These drug targets were cross-validated through literature showing 77.14% accuracy. Thus, the idea behind this work was to develop a fast, robust and generic program capable of finding drug targets in bacteria, which has been fulfilled satisfactorily.
Background:
Drug discovery is a vast process, which includes various stages and trials; no wonder even after the investment of huge amount of money and time pharmaceutical companies takes decades to launch a new product to the market [1] . Among all these stages a very primary stage is the drug target identification process under which we screen possible drug targets within a pathogen without harming the host; therefore for this a clear understanding of host-pathogen interactions is required. Human genome sequencing as well as sequencing of many pathogens in the recent years has produced a huge amount of data, which are quite useful for comparing both human and pathogenic at genomic level, and with the modern computational techniques this comparison can be done in no time [2, 3] . Thus filtering out huge number of protein has become much easier and convenient leaving very less number of proteins for wet lab cross validation saving both time and money.
There are many existing computational techniques for drug target identification known but only some are fully automated. T-iDT is one such potential drug target identification tool validated in Mycobacterium tuberculosis [4] , which extracts drug targets, which are essential and non, homologous to human by comparing data with the Database of Essential Genes (DEG) [5] and human protein database. But it is stand-alone software and will not show updates of DEG database, which can only be done manually. Here, we have designed a Perl program named Dtar-Finder and fully automated the subtractive genomic approach for drug target identification in bacteria [6, 7, 8]. Dtar-Finder performs the following functions: 1) Identification of drug targets in bacteria 2) Characterization of the identified targets based on its druggability and broad-spectrum ability. This program is scripted under 6 modules where module 1-4 identifies probable drug target candidates and module [5] [6] ©Biomedical Informatics (2019) characterizes the identified targets. The objective of this program is to not only to screen non-homologous human proteins (eliminates the chances of cross-reactivity of drug with similar human protein) and essential protein (required for bacterial survival) [9] but also filter out proteins homologous to anti-targets (human essential proteins) [10] and human gut microbiota (resides in gastrointestinal tract of healthy human) [11] . Special feature added in Dtar-Finder also characterized the identified targets on the basis of its druggability (homology search against Drugbank database) and broad-spectrum ability (homology search against pathogen database). Further, we have tested the performance of this userfriendly robust program. 
Output:
Dtar-Finder produces 3 result files (1) drug_targets.fasta -It carries potential drug targets ID and their corresponding sequence in the fasta format (2) drugability_result.fasta -It carries homologous drug bank targets (3) broad_spectrum_result -It carries the number of homologous pathogens against each target. The calculated sensitivity and specificity for the 100 protein dataset validates the performance of the program tabulated in Table 1 which clearly shows that the specificity score is having better results compared to sensitivity. Also, for 3572 proteins of C. botulinum, 35 potential drug targets have been predicted, out of which 16 drug targets were broad spectrums candidates and 8 drug targets were found to be druggable while remaining were seemed to be 'novel' targets (Table 2) . These results were further cross-validated through literature and 27 drug targets with similar functions (functionality of 3 hypothetical proteins were predicted using INTERPROSCAN)
[15] were found to be acting as a drug target in other bacteria whereas 8 targets did not show any result. That means the cross validation produced results with 77.14% of accuracy.
Caveats:
Dtar-Finder provides results, which are fully computational, based and uses BLAST program for sequence similarity search hence; all the limitations related to this in-silico techniques are equally applicable to this script output. Here, we have collected reference files from different databases therefore all the limitations related with these databases are again applicable to our script result. Although the sensitivity and specificity scores are better but still needs further improvement. Also a detail investigation and wet lab validation of the result is required.
Future development:
In future we can further include other qualitative characterization features such as cellular localization, functionality analysis of hypothetical proteins, etc in the later version of Dtar-Finder.
